Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.

Insulin Glargine Safety in Pregnancy

Open access
Pollex, Erika K., Feig, Denice S., Lubetsky, Angelika, Yip, Paul M., Koren, Gideon · 2010 · Diabetes Care

Abstract

OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence of hypoglycemia provide potential advantages for its use in pregnancy. However, the placental pharmacokinetics of insulin glargine have not been studied. Therefore, the objective of this study was to determine whether insulin glargine crosses the human placenta using the human perfused placental lobule technique. RESEARCH DESIGN AND METHODS: Placentae were obtained with informed consent after elective cesarean section delivery of noncomplicated term pregnancies. Insulin glargine, at a therapeutic concentration of 150 pmol/l (20 μU/ml) was added to the maternal circulation. Additional experiments were carried out at insulin glargine concentrations 1,000-fold higher than therapeutic levels (150, 225, and 300 nmol/l). A subsequent perfusion for which the maternal circuit remained open and insulin glargine was continuously infused at 150 pmol/l was completed for further confirmation of findings. The appearance of insulin glargine in the fetal circulation was analyzed by a chemiluminescence immunoassay. RESULTS: Results from perfusions carried out at therapeutic concentrations (150 pmol/l) of insulin glargine showed no detectable insulin glargine in the fetal circuit. After perfusion with very high insulin glargine concentrations of 150, 225, and 300 nmol/l, the rate of transfer remained low at 0.079 ± 0.01, 0.14, and 0.064 pmol · min−1 · g tissue−1, respectively. CONCLUSIONS: Insulin glargine, when used at therapeutic concentrations, is not likely to cross the placenta.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-1045

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Maternal and fetal insulin concentrations during 3-h perfusions in the presence of therapeutic levels (150 pmol/l) of insulin glargine (n = 5). ▼, maternal open circuit; ■, maternal closed circuit; ●, fetal.
Figure 1 Maternal and fetal insulin concentrations during 3-h perfusions in the presence of therapeutic levels (150 pmol/l) of insulin glargine (n = 5). ▼, maternal open circuit; ■, maternal closed circuit; ●, fetal.CC BY-NC-ND · PubMed Central
Figure 2 Disappearance of insulin from the maternal compartment over 180 min of perfusion in the presence of insulin glargine concentrations 1,000-fold greater than therapeutic (150–300 nmol/l) (n = 4). ■, maternal reservoir concentration 150 nmol/l; ●, maternal reservoir concentration 300 nmol/l; ▲, maternal reservoir concentration 150 nmol/l; ♦, maternal reservoir concentration 225 nmol/l.
Figure 2 Disappearance of insulin from the maternal compartment over 180 min of perfusion in the presence of insulin glargine concentrations 1,000-fold greater than therapeutic (150–300 nmol/l) (n = 4). ■, maternal reservoir concentration 150 nmol/l; ●, maternal reservoir concentration 300 nmol/l; ▲, maternal reservoir concentration 150 nmol/l; ♦, maternal reservoir concentration 225 nmol/l.CC BY-NC-ND · PubMed Central
Figure 3 Appearance of insulin in the fetal compartment after perfusions in the presence of maternal insulin glargine concentrations 1,000-fold greater than therapeutic (150–300 nmol/l) (n = 4). ■, maternal reservoir concentration 150 nmol/l; ●, maternal reservoir concentration 300 nmol/l; ▲, maternal reservoir concentration 150 nmol/l; ♦, maternal reservoir concentration 225 nmol/l.
Figure 3 Appearance of insulin in the fetal compartment after perfusions in the presence of maternal insulin glargine concentrations 1,000-fold greater than therapeutic (150–300 nmol/l) (n = 4). ■, maternal reservoir concentration 150 nmol/l; ●, maternal reservoir concentration 300 nmol/l; ▲, maternal reservoir concentration 150 nmol/l; ♦, maternal reservoir concentration 225 nmol/l.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 104

Metadata

Authors
Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G.
Affiliations
  • University of Toronto (CA)
  • Mount Sinai Hospital (CA)
  • Hospital for Sick Children (CA)
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Corresponding author
Koren, Gideon
Venue
Diabetes Care
Published
2009-10-06
Volume
33
Issue
1
Pages
29-33
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2083261524
Cited by
104
References
26
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 10 · 2017: 3 · 2016: 4 · 2015: 7 · 2014: 5 · 2013: 10 · 2012: 7
FWCI
11.04
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Hospital for Sick Children
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
insulin glargine, placental transfer, pregnancy, insulin analogues, placental perfusion, diabetes in pregnancy, drug safety in pregnancy
MeSH terms
Insulin Glargine, Biological Transport, Female, Fetal Blood, Humans, Hypoglycemic Agents, Insulin, Maternal-Fetal Exchange, Perfusion, Placenta, Pregnancy, Insulin, Long-Acting, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin Glargine Safety in Pregnancy. https://app.cochat.ai/papers/10.2337/dc09-1045
The paper
Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G. (2010). Insulin Glargine Safety in Pregnancy. Diabetes Care. https://doi.org/10.2337/dc09-1045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.